Edoardo Sarti, Cédric Dollé, Rebekka Wolfensberger, Katharina Kusejko, Doris Russenberger, Simon Bredl, Roberto F Speck, Melanie Greter, Jan H Rueschoff, Lucas Boeck, Dat Mai, Ana N Jahn, Elizabeth S Gold, Dong Liu, Alan H Diercks, Peter Sander, Gregory S Olson, Johannes Nemeth
{"title":"c-Myc inhibits macrophage antimycobacterial response in Mycobacterium tuberculosis infection","authors":"Edoardo Sarti, Cédric Dollé, Rebekka Wolfensberger, Katharina Kusejko, Doris Russenberger, Simon Bredl, Roberto F Speck, Melanie Greter, Jan H Rueschoff, Lucas Boeck, Dat Mai, Ana N Jahn, Elizabeth S Gold, Dong Liu, Alan H Diercks, Peter Sander, Gregory S Olson, Johannes Nemeth","doi":"10.1093/infdis/jiaf456","DOIUrl":null,"url":null,"abstract":"Mycobacterium tuberculosis (MTB) remains a major cause of global mortality, yet natural immunity prevents disease in more than 90% of exposed individuals. Interferon gamma (IFN-γ) is a critical regulator of innate immunity and enhances macrophage antimicrobial responses. In this study, we investigated how IFN-γ timing influences macrophage control of MTB. We found that pre-infection IFN-γ exposure primes macrophages for enhanced bacterial control by activating key antimicrobial pathways, whereas post-infection exposure fails to confer this benefit. Using unbiased in vitro systems approaches, we identified c-Myc signaling as a central determinant of macrophage antimycobacterial function. To manipulate c-Myc in primary cells, we developed a tetracycline-inducible lentiviral system for c-Myc inhibition and overexpression. c-Myc inhibition via Omomyc enhanced macrophage bacterial control through mTORC1-dependent metabolic reprogramming and nitric oxide production. In vivo analyses, including murine models and human clinical histopathology, revealed strong associations between c-Myc expression, MTB persistence, and active tuberculosis, implicating c-Myc as a mediator of immune privilege in MTB infection and a promising target for host-directed therapies to enhance macrophage function.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mycobacterium tuberculosis (MTB) remains a major cause of global mortality, yet natural immunity prevents disease in more than 90% of exposed individuals. Interferon gamma (IFN-γ) is a critical regulator of innate immunity and enhances macrophage antimicrobial responses. In this study, we investigated how IFN-γ timing influences macrophage control of MTB. We found that pre-infection IFN-γ exposure primes macrophages for enhanced bacterial control by activating key antimicrobial pathways, whereas post-infection exposure fails to confer this benefit. Using unbiased in vitro systems approaches, we identified c-Myc signaling as a central determinant of macrophage antimycobacterial function. To manipulate c-Myc in primary cells, we developed a tetracycline-inducible lentiviral system for c-Myc inhibition and overexpression. c-Myc inhibition via Omomyc enhanced macrophage bacterial control through mTORC1-dependent metabolic reprogramming and nitric oxide production. In vivo analyses, including murine models and human clinical histopathology, revealed strong associations between c-Myc expression, MTB persistence, and active tuberculosis, implicating c-Myc as a mediator of immune privilege in MTB infection and a promising target for host-directed therapies to enhance macrophage function.